Imidazoline type 1 receptor (I1 receptor)

The **Imidazoline type 1 receptor (I1 receptor)** is a specific cell-surface binding site originally identified by its affinity for antihypertensive compounds such as clonidine and more selective imidazoline drugs like moxonidine and rilmenidine. It is widely distributed in the plasma membranes of neurons within the rostral ventrolateral medulla, where it plays a major role in the central regulation of blood pressure through inhibition of sympathetic nervous system activity[1][2][4][5][6]. Activation of this receptor decreases sympathetic tone, lowers catecholamine release, and results in vasodilation without significant sedation—a key distinction from α2-adrenergic receptor agonists[3][4]. The I1 receptor is an orphan receptor, with its precise molecular identity still under investigation, but its pharmacology and central actions are well characterized[4][7]. It has therapeutic significance for hypertension management and has been implicated in metabolic syndrome and potentially in neuroprotection and inflammatory modulation[5][6]. Key drugs targeting the I1 receptor include moxonidine and rilmenidine, both of which lower blood pressure by centrally mediated sympathoinhibition with fewer side effects than older centrally acting antihypertensives[3][4][6][8][9].

Other names

I1-imidazoline receptorI1 receptorI₁-imidazoline-binding site

Agonists at the I1 receptor decrease sympathetic tone centrally, leading to vasodilation and reduced blood pressure Activation linked to increased diacylglycerol via phosphatidylcholine-selective phospholipase C Some agents affect both imidazoline receptors and α2-adrenergic receptors